Nat. Rev. Neurol. doi: /nrneurol

Slides:

Advertisements

Similar presentations

Table 3 Limb-girdle muscular dystrophy standardized data collection form and HPO mapping Thompson, R. & Straub, V. et al. (2016) Limb-girdle muscular dystrophies.

Advertisements

Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Life expectancy at birth in all countries included

MRI and possible differentiating features with nonconventional MRI

Figure 1 Perivenous distribution of multiple sclerosis lesions

Figure 4 Paradoxical immune reconstitution inflammatory syndrome

Figure 2 The US Centers for Disease Control and

Figure 4 Interplay between acute kidney injury (AKI),

Figure 4 Time course of the development of physiological changes

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 General framework of brain–computer interface (BCI) systems

Figure 2 The new concept of prodromal RBD

Figure 1 The topographical model of multiple sclerosis, clinical (A) and subclinical (B) views The topographical model of multiple sclerosis, clinical.

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Proportion of patients for whom NEDA

Figure 5 Number of AHSCT procedures for

Figure 4 Neuromyelitis optica spectrum disorder brain lesions

Figure 5 Corticosteroid treatment can reduce brain

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Allele frequency and effect size for ALS-associated genes

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Hypothetical mechanisms of smoking-associated

Nat. Rev. Urol. doi: /nrurol

Figure Brain MRI of the patient throughout the disease course(A) Brain MRI at the time of cerebral toxoplasmosis diagnosis (a) and after 1 month of toxoplasmosis.

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Principles of therapeutic ultrasound

Figure 1 Clinical correlates of neurodegeneration in MS

Figure 4 Flow chart of the MDS MSA Study Group aims

Figure 2 Examples of lesions with and without central veins

Figure 3 Genetic pleiotropy in ALS

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Evolution of multiple sclerosis

Figure 1 The trajectory of cognitive ageing

Nat. Rev. Neurol. doi: /nrneurol

Figure 3 Stroke-related deaths and DALYs by country development status

Figure 2 Age-specific prevalence of common comorbidities

Figure 4 11C-PK11195-PET scans showing the evolution of neuroinflammation in a patient after stroke Figure 4 | 11C-PK11195-PET scans showing the evolution.

Figure 2 Carotid artery inflammation detected using 68Ga-DOTATATE-PET

Figure 6 Combining population-wide and high-risk strategies

Nat. Rev. Urol. doi: /nrurol

Brain MRI scans for the patient.

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Urol. doi: /nrurol

Figure 2 Logistical requirements for autologous

Figure 1 Cerebral MRI during the disease course Cerebral MRI with multiple cerebral supratentorial lesions during the disease course: periventricular lesions.

Figure 3 Potential interplay between physiological

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Clinical aspects of LGMD subtypes

Figure 1 The VEGF family of growth factors

Figure 1 Tau PET images in patients with Alzheimer disease

Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Timing of the effects of deep brain stimulation

Figure 5 Interaction between infarction and amyloid deposition

Figure 1 A large number of genes are potentially associated with CIPN

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Histopathological features in CIDP

Figure 1 Annualized percentage brain volume change

Figure 2 Network connections of the hypothalamus

Figure 2 Aβ-PET scans obtained using different tracers

Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis The rate.

Presentation transcript:

Nat. Rev. Neurol. doi:10.1038/nrneurol.2015.157 Figure 2 Serial T1-weighted MRI scans in a patient with multiple sclerosis Figure 2 | Serial T1-weighted MRI scans in a patient with multiple sclerosis. a | Baseline scan. b–d | Regular scans over a 6-year follow-up period. Disease progression can be seen in the form of the increasing size of ventricular and subarachnoid spaces. These changes reflect brain volume loss over time, indicating progressive neurodegeneration. Wattjes, M. P. et al. (2015) MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients Nat. Rev. Neurol. doi:10.1038/nrneurol.2015.157